tbuckley/cabot-search huggingface dataset:
Creating patient engagement infrastructure in bladder cancer research prioritization.
Authors: Angela Smith, Stephanie Chisolm, Diane Zipursky Quale, John L. Gore
Journal: Journal of Clinical Oncology (2016)

e18168 Background: Patient engagement is the meaningful involvement of patients throughout the research process, beginning with topic selection and ending with dissemination. Our objective was to create a patient engagement infrastructure in bladder cancer, which would establish a systematic method of topic prioritization as well as a repository of engaged patients for future research. Methods: Using a combination of online, print, and word-of-mouth advertisement through the Bladder Cancer Advocacy Network (BCAN), we invited bladder cancer patients and caregivers to join the Patient Survey Network (PSN) and provide demographic and clinical data. During the BCAN 2015 Think Tank meeting, patients & stakeholders were asked to identify important research questions facing the bladder cancer community. Using the Delphi method, these questions were ranked and discussed during a round-table discussion with stakeholders. The top 3 questions for non-invasive, invasive and metastatic bladder cancer were sent to members of the PSN, who ranked questions in order of importance and included free-text questions. Results: The PSN currently comprises 781 participants, including 540 patients and 51 caregivers, of whom 62% were male and 95% were white, with broad representation across the US. Among patients, 62% identified with non-invasive disease, 34% invasive, and 4% metastatic. 94% were willing to be contacted to participate in future research. The PSN ranked the top 3 questions, and results were discussed during a final conference call with multiple stakeholders. A final prioritized list was created for each disease stage (12 questions for non-invasive, 7 for invasive, & 5 for metastatic). Results were disseminated through advertisement, email, funding agencies, and future journal publication. Conclusions: We developed a patient engagement infrastructure for bladder cancer care. Prioritized research topics will inform funders and researchers of research questions important to bladder cancer patients. The PSN will also foster patient engagement throughout the research process by serving as a repository for engaged patients interested in trial design, conduct, and dissemination. The PSN can serve as a model in other cancer sites.
Residual Vein Thrombosis Improves Screening for Occult Cancer: Results On 537 Patients with Idiopathic Deep Vein Thrombosis.
Authors: Sergio Siragusa, Alessandra Malato, Fabio Fulfaro, Giorgia Saccullo, Domenica Caramazza, Giusy Pizzo, Lucio lo Coco, Nicola Gebbia
Journal: Blood (2009)
The host response and colon cancer prognosis
Authors: C. K. Ryan, K. Elias, D. M. Sahasrabudhe, S. Eberly, A. A. Khorana
Journal: Journal of Clinical Oncology (2004)

9565 Background: Recent data suggests that the host response may influence outcomes in colon cancer. We studied the prognostic significance of various components of the host response to colon cancer, including tumor-associated macrophages (TAM), tumor-infiltrating lymphocytes and dendritic cells. Methods: We identified 130 consecutive stage II and III colon cancer patients seen at the University of Rochester from 1990–95. CD8+ T cells were examined by immunohistochemistry in paraffin-embedded primary colon tumors at three locations: intratumoral, along the invasive margin, and in stroma. Intratumoral, marginal and stromal lymphocytes were counted by two pathologists using a previously published scoring system. TAM (identified by CD68 immunostaining) and dendritic cells (identified by CD86 immunostaining) were semiquantitatively graded by their degree of infiltration on a scale from 0 to 3. Results: 73% of patients demonstrated TAM infiltration in the stroma. Intratumoral CD8+ T cells were present in 25% patients, stromal CD8+ T cells were present in 18% patients, and a heavy marginal infiltrate was present in 29% of patients. Median survival was 7.9 years [95% CI (5.0, 9.9) years] in patients with TAM infiltration, a two-fold increase over median survival of 3.1 years [95% CI (1.4, 5.3) years] in patients without TAM infiltration (p=0.0075). Presence of TAM was associated with higher grades of intratumoral CD8+ T cell infiltration (Spearman correlation, 0.24, p=0.007), as well as stromal CD8+ T cell infiltration (Spearman correlation, 0.27, p=0.002). However, intratumoral or stromal T cells alone were not associated with improved outcomes. No significant dendritic cell infiltration was observed in a subset of cases (n=10). Conclusions: TAM are associated with a two-fold increase in median survival in Stage II and III colon cancer. TAM correlate with cytotoxic T cell infiltration into tumor cell nests and tumor stroma. This suggests that TAM have direct tumoricidal effects and may activate T cells by functioning as antigen-presenting cells. Novel approaches that can further augment this immune response deserve clinical study. No significant financial relationships to disclose.
Health information seeking preferences of Mexican cancer survivors: Creating an evidence base for the design of high-quality communication programs.
Authors: Enrique Soto Perez De Celis, Edgar Baltazar-Avalos, Lorena Ali Guadalupe Rocha-Rojo, Patricia Rojo-Castillo, Yanin Chavarri Guerra
Journal: Journal of Clinical Oncology (2016)

190 Background: In order to improve the quality of the communication between the healthcare system and cancer survivors, it is fundamental to understand their preferred sources of health information. In low and middle-income countries (LMICs), little is known regarding which sources are used and trusted the most. This information is crucial to develop effective communication aimed at achieving high-quality equitable cancer care. Our objective was to explore the preferred sources of health information in Mexico, and to understand which factors influence these choices. Methods: We examined sources of health information among cancer survivors in Mexico City using questions from the Spanish Version of the Health Information National Trends Survey (HINTS). The characteristics of survivors who preferred the internet were compared with those who preferred other sources (doctors, printed materials, family members, organizations) using Fisher’s exact test. Logistic regression was used to assess the effects of patient characteristics on health information-seeking. Results: Of 148 participants, 82 (56%) had internet access. Of the 88 patients who had sought health information, 61 (69%) listed the internet as their preferred source. Those 65 and older were less likely to seek health information, regardless of the source (OR 0.17, p &lt; 0.0001). Survivors who preferred the internet were more likely to be younger (p = 0.001), male (p = 0.003) and to have a higher educational level (p = 0.009). Comorbidities, stage, cancer type, and time from diagnosis had no effect on patient preferences. Doctors were the most trusted source of information (85%), followed by the internet (28%) and government agencies (23%). Conclusions: Mexican patients who seek health information online are more likely to be young educated males. Doctors represent the most trusted source of information, particularly for patients from vulnerable populations (such as older women with low educational levels). High-quality healthcare information programs in LMICs should be designed taking these behaviors into account, and patients should continue to receive health information via their most trusted sources.
A Mutation in a GATA-1 Binding Site 5′ to the Gγ-Globin Gene (nt -567, T&amp;gt;G) May Be Associated with Increased Levels of Fetal Hemoglobin.
Authors: H.Y. Luo, D. Mang, G.P. Patrinos, C.J.Y. Wu, S.H. Eung, F. Pourfarzad, J. Whitacre, C.G. Rosenfield, P.R. Daoust, A. Braun, F.G. Grosveld, M.H. Steinberg, D.H.K. Chui
Journal: Blood (2004)
GW27-e0459 Attainment of acc/aha recommended ldl-c lowering with statin and ezetimibe+statin therapies
Authors: Peter P Toth, Harold Bays, Michel Farnier, Erin Jensen, Joanne E Tomassini, Adam Polis, JoAnne Foody, Andrew M Tershakovec
Journal: Journal of the American College of Cardiology (2016)
TCT-786 A Single Center Experience Of Zilver PTX For Femoro-Popliteal Lesions
Authors: Won Yu Kang, Umberto Campia, Romain Didier, Nelson L. Bernardo, Smita I. Negi, Sarkis Kiramijyan, Edward Koifman, Nevin C. Baker, Michael J. Lipinski, Ricardo O. Escarcega, Rebecca Torguson, Ron Waksman
Journal: Journal of the American College of Cardiology (2015)
Landscape of Genetic Alterations in Adult T-Cell Leukemia/Lymphoma
Authors: Keisuke Kataoka, Yasunobu Nagata, Akira Kitanaka, Yasushi Totoki, Jun-ichirou Yasunaga, Shinichi Kotani, Aiko Sato-Otsubo, Masashi Sanada, Yuichi Shiraishi, Teppei Shimamura, Kenichi Chiba, Hiroko Tanaka, Hiromichi Suzuki, Yusuke Sato, Yusuke Shiozawa, Tetsuichi Yoshizato, Ayana Kon, Kenichi Yoshida, Masakatsu Hishizawa, Wataru Munakata, Hiromi Nakamura, Natsuko Hama, Kotaro Shide, Yoko Kubuki, Tomonari Hidaka, Takuro Kameda, Ken Ishiyama, Shuichi Miyawaki, Ryohei Ishii, Osamu Nureki, Genta Nagae, Hiroyuki Aburatani, Satoru Miyano, Akifumi Takaori-Kondo, Toshiki Watanabe, Masao Matsuoka, Tatsuhiro Shibata, Kazuya Shimoda, Seishi Ogawa
Journal: Blood (2014)
Autologous Stem Cell Transplantation after Myeloablative Therapy in First Remission May Be Beneficial in Patients with Advanced Stage Follicular Lymphoma after Front-Line Therapy with R-CHOP. An Analysis of Two Consecutive Studies of the German Low Grade Lymphoma Study Group (GLSG)
Authors: Wolfgang Hiddemann, Christian Buske, Michael Kneba, Martin Dreyling, Norbert Schmitz, Eva Lengfelder, Rudolf Schmits, Marcel Reiser, Bernd Metzner, Michael Unterhalt
Journal: Blood (2008)
AB0041 B-cell activating factor (BAFF) binding receptors (BBR) on B cells: characterization in patients with rheumatoid arthritis (RA) receiving anti-TNF-alpha agent infliximab (IFX)
Authors: D. Hernández, I.D. de la Torre, G. Cambridge, L. Martinez, J.C. Nieto, J. Ovalles, J. Barrios, C. González, M. Montoro, J. Lόpez-Longo, I. Monteagudo, L. Carreño, L. Valor
Journal: Annals of the Rheumatic Diseases (2013)

<h3>Objectives</h3> To evaluate BBR (BAFF-R, TACI and BCMA) expression on B-cells in response to the treatment with the anti-TNF-alpha agent infliximab in RA patients <h3>Methods</h3> We assessed naïve and memory B-cells expressing BBR in peripheral blood in 23 patients with RA on infliximab treatment: 12 in no-remission (DAS28&gt;3.2), 11 in remission (DAS28&lt;2.6) and healthy controls (HC; n=12) using monoclonal antibodies to CD19, CD27, IgD, CD38, BAFF-R, TACI and BCMA by multiparametric flow cytometry. <h3>Results</h3> Despite similar BAFF-R expression on naïve and memory B-cells of RA patients (remission/no-remission) compared to HC, we found increased % of CD27+ memory B-cells TACI+ in RA patients (remission/non remission) compared to HC (p=0.004 and p=0.01, respectively). A significantly lower % of B-cells expressed BCMA on naive population for both remission/ no-remission RA patients vs. HC (naïve mature, CD19+IgD++CD38-, p=0.01 and p=0.001, respectively, naïve transitional CD19+IgD+,CD38++,p=0.0007 and p=0.01, respectively) and on memory population only for RA patients in remission compared to HC (plasmablast CD19+IgD-CD38 p=0.03, and post-GC memory CD19+,IgD-CD38++, p=0.04). <h3>Conclusions</h3> Major BBR alterations are present in RA patients treated with the anti-TNF agent infliximab; blocking TNF-alpha could restore partly the defect on the maturation-survival process in RA patients B-cells, down-regulating BCMA and preventing short lived B-cells from becoming antibody-producing plasma cells. However, RA patients on anti-TNF therapy show a increased TACI and decreased BCMA expression in memory B-cells; defects in B-cell pool might persist due to contributions by other soluble and/or cellular mediators. <h3>Disclosure of Interest</h3> None Declared
A norovirus intervariant GII.4 recombinant in Victoria, Australia, June 2016: the next epidemic variant?
Authors: Leesa Bruggink, Michael Catton, John Marshall
Journal: Eurosurveillance (2016)

A norovirus recombinant GII.P4_NewOrleans_2009/GII.4_Sydney_2012 was first detected in Victoria, Australia, in August 2015 at low frequency, and then re-emerged in June 2016, having undergone genetic changes. Analysis of 14 years' surveillance data from Victoria suggests a typical delay of two to seven months between first detection of a new variant and occurrence of a subsequent epidemic linked to that variant. We consider that the current recombinant strain has the potential to become a pandemic variant.
Front-Line, Dose-Escalated Immunochemotherapy Is Associated with a Significant PFS (but not OS) Advantage in 401 Patients (Pts) with Double-Hit Lymphomas (DHL): A Systematic Review and Meta-Analysis
Authors: Christina Howlett, Daniel J. Landsburg, Elise A. Chong, Sonya J Snedecor, Stephen J. Schuster, Tina Marie Green, Jonathon B. Cohen, Jakub Svoboda, Sunita Dwivedy Nasta, Tatyana Feldman, Allison Rago, Danielle Land, Kristy M. Walsh, Andre Goy, Anthony R. Mato
Journal: Blood (2014)
TCT-445 The prognostic significance of repeat revascularization after percutaneous coronary intervention: an analysis of 41,180 patients from the British Columbia Cardiac Registry
Authors: M Bilal Iqbal, Michael Fryer, Imad J. Nadra, Lillian Ding, Anthony Fung, Eve Aymong, Albert W. Chan, Steven Hodge, Simon Robinson, Anthony Della Siega
Journal: Journal of the American College of Cardiology (2015)
Observational Cohort Studies and the Challenges of In Silico Experiments
Authors: Colin G. Walsh, Kevin B. Johnson
Journal: JAMA Oncology (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Oncology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Oncology journal
Pilot Evaluation of the Value of FDG PET-CT after One and Two Cycles of Salvage Chemotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s and Hodgkin’s Lymphoma
Authors: Andrew Hodson, Tara Barwick, Brigitta Marson, Nick Maisey, Kavita Raj, George Mikhaeel, Majid A. Kazmi, Tom Nunan, Michael O’Doherty, Paul Fields
Journal: Blood (2008)
Similar Outcomes Using Myeloablative Versus Reduced Intensity and Non-Myeloablative Allogeneic Transplant Preparative Regimens for AML or MDS: From the Center for International Blood and Marrow Transplant Research
Authors: Selina Luger, Olle Ringden, Waleska S. Peréz, Mei-Jie Zhang, John F. DiPersio, Jorge Sierra, Martin Tallman, Daniel J. Weisdorf, Michael Pulsipher
Journal: Blood (2008)
TCT-632 Implementation of a Moderate Sedation Protocol for Transfemoral Transcatheter Aortic Valve Replacement: A Review at 6 Months
Authors: Peter Neuburger, Ryan Potosky, Patricia Ursomanno, Ramsey Abdallah, Muhamed Saric, Ricardo J. Benenstein, Cezar S. Staniloae, James Slater, Michael Querijero, Mathew Williams
Journal: Journal of the American College of Cardiology (2015)
Human Neutrophil Peptides (HNPs) Enhance Thrombus Formation Under Flow By Inhibiting Proteolytic Activity of Plasma ADAMTS13 Metalloprotease
Authors: Vikram G. Pillai, Jialing Bao, Jenny McDaniel, Catherine B. Zander1, Wenjing Cao, Khalil Bdeir, Douglas B. Cines, X. Long Zheng
Journal: Blood (2015)
A Hyaluronidase-Responsive Nanoparticle-Based Drug Delivery System for Targeting Colon Cancer Cells
Authors: Mingzhen Zhang, Changlong Xu, Liuqing Wen, Moon Kwon Han, Bo Xiao, Jun Zhou, Yuchen Zhang, Zhan Zhang, Emilie Viennois, Didier Merlin
Journal: Cancer Research (2016)

The ability of nanoparticles to target tumors and to enable site-specific drug release provides a unique system for the delivery of effective therapy with reduced toxic side effects. In this study, we used mesoporous silica nanoparticles (MSN) to fabricate a targeted drug delivery system that is responsive to hyaluronidase (HAase). Following engraftment of desthiobiotin onto the surface of MSN, a streptavidin complex was generated, which was functionalized with biotin-modified hyaluronic acid (HA) to enable controlled drug release at cancer cells expressing HAase. Various technologies were used to confirm the successful fabrication of this MSN-based nanocarrier system for targeted drug delivery. In vitro analyses showed that the release of doxorubicin hydrochloride (Dox) was accelerated significantly in the presence of biotin or HAase and accelerated further in the presence of biotin and HAase. Uptake by cancer cells was mediated efficiently by CD44 receptor-mediated endocytosis and the MSN exhibited good biocompatibility in vitro and in vivo MSN-HA/Dox nanoparticles induced apoptosis in cancer cells more efficiently than free doxorubicin and inhibited tumor growth with minimal systemic toxicity in vivo Collectively, our findings offered a preclinical proof of concept for a novel targeted drug delivery carrier system for cancer therapy. Cancer Res; 76(24); 7208-18. ©2016 AACR.
Expression of Activated Molecules on CD5+ b Cells in Autoimmune Hemolytic Anemia
Authors: Hongli Zhu, Limin Xing, Hong Liu, Huaquan Wang, Rong Fu, Yuhong Wu, Wen Qu, Guojin Wang, Jing Guan, Jia Song, Zonghong Shao
Journal: Blood (2015)
A randomized phase II study evaluating the optimal sequencing of sipuleucel-T and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Immune results.
Authors: Emmanuel S. Antonarakis, Adam S Kibel, George Adams, Lawrence Ivan Karsh, Aymen Elfiky, Neal D. Shore, Nicholas J. Vogelzang, John M. Corman, Robert Claude Tyler, Candice McCoy, Yang Wang, Nadeem A. Sheikh, Charles G. Drake
Journal: Journal of Clinical Oncology (2013)

5016 Background: ADT is a standard treatment for men with BRPC after failure of local therapy, and has immunomodulatory effects. Sipuleucel-T is an autologous cellular immunotherapy approved for asymptomatic/minimally symptomatic metastatic castrate resistant prostate cancer. The STAND trial (NCT01431391) aimed to evaluate optimal sequencing of sipuleucel-T and ADT in men with BRPC at high risk for metastases (ie PSA doubling time ≤12 mo). Methods: Men were randomized (1:1) to Arm 1: sipuleucel-T followed by ADT (2 wks after 3rd infusion); or Arm 2: ADT (3 mo lead in) followed by sipuleucel-T. All men had 3 doses of sipuleucel-T and 12 mo of ADT (45 mg leuprolide SQ at 6 mo intervals). The primary endpoint is cellular immune response (ELISPOT to PA2024 [PAP-GMCSF]). Secondary endpoints are humoral and cytokine responses, product parameters and safety. Results: 68 men were randomized. Preliminary data show higher levels of serum cytokines in Arm 2 vs Arm 1, with a pattern suggesting a mixed T H 1/T H 2 cellular immune response; elevations were seen in T H 1 (IFNγ, IL 12), T H 2 (IL 4, 5, 10, 13) and T H 17 (IL 17) subsets (all P&lt;.05). The increase in T H 1 cytokines was consistent with a trend toward higher PA2024-specific ELISPOT responses 2 wk after the 3rd sipuleucel-T infusion in Arm 2 vs Arm 1 (40.5 vs 12.8 spots; P=.086), suggesting increased T cell activation in Arm 2. Antigen-specific humoral responses were induced in both arms with no differences yet observed between arms. Sipuleucel-T product parameters were roughly equivalent in both arms with APC activation data indicating a robust prime-boost effect. Conclusions: While confirmation is required, these preliminary data suggest that tumor-specific T cell responses and broad based immune responses are augmented when sipuleucel-T is given after rather than before ADT initiation. These data are consistent with preclinical studies showing that ADT enhances T cell activity, and provide preliminary evidence that combining ADT with sipuleucel-T may augment adaptive immunity. Further follow up will determine whether augmented immune responses correlate with clinical parameters (eg PSA recurrence). Clinical trial information: NCT01431391.
First Description Of a t(10;11)(q22;q23)/MLL-TET1 Reciprocal Translocation In a T Lymphoblastic Lymphoma With Subsequent Lineage Switch To Acute Myelomonocytic Myeloid Leukemia
Authors: Antoine Ittel, Eric Jeandidier, Nathalie Perrusson, Catherine Humbrecht, Bruno Lioure, Isabelle Mazurier, Caroline Mayeur-Rousse, Carine Gervais, Catherine Helias, Sylvie Thiebault, Felix Lerintiu, Laurent Mauvieux
Journal: Blood (2013)
Eradication of B Cell Malignancies by Anti-3rd Party CTLs: A Novel Role for MHC Class I.
Authors: Assaf Lask, Polina Goichberg, Rinat Goren-Arbel, Oren Milstein, Shraga Aviner, Ilan Feine, Tirza Klein, Alain Berrebi, Yair Reisner
Journal: Blood (2007)
Multicenter phase II study of triple combination with S-1 and cisplatin (CDDP) plus paclitaxel (TXL) in patients with advanced gastric cancer
Authors: H. Iwase, T. Tsuzuki, M. Shimada, K. Ina, M. Shinoda, J. Kumada, S. Okamura, J. Haruta, M. Sugihara, H. Goto
Journal: Journal of Clinical Oncology (2008)

4539 Background: S-1 plus CDDP is active and tolerable against advanced gastric cancer (AGC) (Iwase H et al., ASCO 2005). The synergistic antitumor effect of TXL and S-1 has been shown in a preclinical study, and so combination chemotherapy with S-1 and CDDP plus TXL might yield a stronger antitumor effect. Our previous phase I study demonstrated the safety and tolerability of this triple combination chemotherapy (Iwase H et al., ASCO 2006). This study evaluated the antitumor activity and toxicities of TXL/S-1/CDDP (TSP) for AGC. Methods: Eligibility criteria included: pathologically confirmed AGC, PS 0–1, >20 years old, and adequate organ functions. TXL (160 mg/m2/day) was administered by infusion for 3 hours on the first day. S-1 (70 mg/m2/day) was administered orally for 14 consecutive days from the first day, and cisplatin (60 mg/m2) was administered as a 24-h infusion on day 14 of every 28- day cycle. Results: Forty-two patients with unresectable locally advanced or metastatic gastric cancer (7 females, 35 males; PS 0/1, 33/9; age 29–75, well differentiated/undifferentiated adenocarcinoma, 23/19) were entered into the multicenter study. A total of 126 cycles were administered (median 3, range 1–8). Forty patients were assessable for toxicity and efficacy and two patients have not been evaluated yet. Grade 3–4 toxicities were: Neutropenia in 47.5% (grade 4: 22.5%), thrombocytopenia in 20.5%, and anemia in 17.5%. regarding nonhematological toxicity, there was no grade 3–4 and grade 2 toxicities were: nausea/vomiting in 37.5%, myalgia in 32.5%, neuropathy in 32.5%, renal dysfunction in 10%, and rush in 5%. All treatment related toxicities were resolved, and no toxic death was reported. CR was observed in 4 and PR was observed in 22 patients (CR rate: 10% (95%CI: 0.7%-19.3%), PR rate: 55% (95%CI: 39.6%-70.4%)). The overall response rate was 65% (95%CI: 50.2%-79.8%), (26/40). The median survival time and progression free survival were 15.2 months and 8.0 months, respectively. Conclusions: Triple combination of TSP showed high antitumor activity and manageable toxicity. This regimen is one of the most powerful candidates to become the standard regimen for AGC. No significant financial relationships to disclose.